Activating mutations in KIT/PDGFRA receptor tyrosine kinases drive gastrointestinal stromal tumors (GIST). KIT/PDGFRA inhibitors. such as imatinib do not evoke an effective cytocidal response. leaving room for quiescence and development of multiple secondary resistance mutations. https://www.spidertattooz.com/Venture-Pouch/